FDAsafety guidance72% confidence
FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Eli Lilly.
Regulatory Analysis
Learn more about actions to accelerate and modernize clinical research across the full continuum of drug development —from the Investigational New Drug (IND) phase to late-stage pivotal trials.
Supporting Context
- Therapeutic area
- Hematology · IDH Inhibition
- Sub-indication
- General
Related signal: Eli Lilly initiates Phase 1 trial of oral IDH inhibitor LY3410738 in hematologic malignancies